Nanobiotix (NBTX) Competitors $3.10 -0.18 (-5.49%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends NBTX vs. TERN, ORIC, VECT, PHAT, TRML, DNA, PROK, ATXS, HUMA, and ANNXShould you be buying Nanobiotix stock or one of its competitors? The main competitors of Nanobiotix include Terns Pharmaceuticals (TERN), ORIC Pharmaceuticals (ORIC), VectivBio (VECT), Phathom Pharmaceuticals (PHAT), Tourmaline Bio (TRML), Ginkgo Bioworks (DNA), ProKidney (PROK), Astria Therapeutics (ATXS), Humacyte (HUMA), and Annexon (ANNX). These companies are all part of the "pharmaceutical products" industry. Nanobiotix vs. Terns Pharmaceuticals ORIC Pharmaceuticals VectivBio Phathom Pharmaceuticals Tourmaline Bio Ginkgo Bioworks ProKidney Astria Therapeutics Humacyte Annexon Terns Pharmaceuticals (NASDAQ:TERN) and Nanobiotix (NASDAQ:NBTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability. Does the MarketBeat Community prefer TERN or NBTX? Terns Pharmaceuticals received 31 more outperform votes than Nanobiotix when rated by MarketBeat users. However, 64.71% of users gave Nanobiotix an outperform vote while only 60.87% of users gave Terns Pharmaceuticals an outperform vote. CompanyUnderperformOutperformTerns PharmaceuticalsOutperform Votes4260.87% Underperform Votes2739.13% NanobiotixOutperform Votes1164.71% Underperform Votes635.29% Does the media favor TERN or NBTX? In the previous week, Terns Pharmaceuticals and Terns Pharmaceuticals both had 3 articles in the media. Terns Pharmaceuticals' average media sentiment score of 1.38 beat Nanobiotix's score of 0.22 indicating that Terns Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Terns Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nanobiotix 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend TERN or NBTX? Terns Pharmaceuticals currently has a consensus price target of $18.30, indicating a potential upside of 212.29%. Nanobiotix has a consensus price target of $12.00, indicating a potential upside of 287.10%. Given Nanobiotix's stronger consensus rating and higher possible upside, analysts plainly believe Nanobiotix is more favorable than Terns Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Terns Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Nanobiotix 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings and valuation, TERN or NBTX? Nanobiotix has higher revenue and earnings than Terns Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTerns Pharmaceuticals$1M497.74-$90.21M-$1.18-4.97Nanobiotix$36.22M4.03-$42.97MN/AN/A Which has more risk and volatility, TERN or NBTX? Terns Pharmaceuticals has a beta of -0.36, meaning that its share price is 136% less volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Do institutionals & insiders have more ownership in TERN or NBTX? 98.3% of Terns Pharmaceuticals shares are held by institutional investors. Comparatively, 38.8% of Nanobiotix shares are held by institutional investors. 15.1% of Terns Pharmaceuticals shares are held by insiders. Comparatively, 3.5% of Nanobiotix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is TERN or NBTX more profitable? Nanobiotix's return on equity of 0.00% beat Terns Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Terns PharmaceuticalsN/A -32.76% -31.33% Nanobiotix N/A N/A N/A SummaryNanobiotix beats Terns Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Nanobiotix News Delivered to You Automatically Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBTX vs. The Competition Export to ExcelMetricNanobiotixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$146.11M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5990.0517.18Price / Sales4.03195.801,117.14116.99Price / CashN/A57.1643.0437.86Price / Book-77.505.094.784.78Net Income-$42.97M$151.83M$120.31M$225.60M7 Day Performance-6.91%-2.13%-1.92%-1.23%1 Month Performance-19.06%-3.10%11.51%3.36%1 Year Performance-59.64%11.54%30.61%16.60% Nanobiotix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBTXNanobiotix2.0828 of 5 stars$3.10-5.5%$12.00+287.1%-53.3%$146.11M$36.22M0.00100News CoverageGap UpHigh Trading VolumeTERNTerns Pharmaceuticals4.2412 of 5 stars$6.96+3.4%$18.30+162.9%-6.8%$591.18M$1M-5.7040Positive NewsGap DownORICORIC Pharmaceuticals3.6849 of 5 stars$8.26-3.1%$18.29+121.4%-3.8%$582.91MN/A-4.6880Insider TradePositive NewsGap DownVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030PHATPhathom Pharmaceuticals2.9933 of 5 stars$8.35+5.8%$23.00+175.4%-9.3%$570.97M$680,000.00-1.48110Gap UpTRMLTourmaline Bio2.4402 of 5 stars$22.11+1.4%$54.00+144.2%+8.7%$566.97MN/A-7.7344Positive NewsDNAGinkgo Bioworks0.5512 of 5 stars$9.62+1.9%$4.58-52.4%N/A$552.96M$251.46M-0.721,218Gap DownPROKProKidney2.0368 of 5 stars$1.90+5.6%$4.50+137.5%-15.6%$552.70MN/A-3.553Gap DownATXSAstria Therapeutics2.0732 of 5 stars$9.70+1.9%$25.60+163.9%+58.0%$547.37MN/A-4.5630News CoverageHUMAHumacyte3.3447 of 5 stars$4.28+4.4%$13.00+203.7%+69.3%$538.68M$1.57M-3.06150Analyst ForecastGap UpANNXAnnexon2.1121 of 5 stars$5.00+12.6%$15.80+216.0%+81.6%$532.97MN/A-4.9060Analyst ForecastNews CoverageGap Down Related Companies and Tools Related Companies Terns Pharmaceuticals Competitors ORIC Pharmaceuticals Competitors VectivBio Competitors Phathom Pharmaceuticals Competitors Tourmaline Bio Competitors Ginkgo Bioworks Competitors ProKidney Competitors Astria Therapeutics Competitors Humacyte Competitors Annexon Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NBTX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nanobiotix S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nanobiotix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NBTX Stock Alerts